This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- Rosalind Ashton, MD, MSc*
- Miriam Weinstein, MD, FRCPC†
- *King's College London School of Medical Education, St. John's Institute of Dermatology, London, United Kingdom
- †The Hospital for Sick Children, Toronto, Ontario, Canada
AUTHOR DISCLOSURE
Dr Ashton has disclosed no financial relationships relevant to this article. Dr Weinstein has disclosed funding from La Roche Posay through her hospital's charitable foundation for a program to teach patients with eczema and their families about the disease and how to manage it; is an advisory board leader/lecturer on eczema for Pfizer; is an advisory board member for Amgen and Pfizer on eczema; is an advisory board consultant for Sanofi Genzyme; is a consultant for Unilever; and is a consultant for Paladin Labs. This commentary does contain a discussion of an unapproved/investigative use of a commercial product/device.
- BPO:
- benzoyl peroxide
- D+A/BPO:
- doxycycline + adapalene/benzoyl peroxide
- DRESS:
- drug reaction with eosinophilia and systemic symptoms
- FDA:
- Food and Drug Administration
- IBD:
- inflammatory bowel disease
- PDL:
- pulsed dye laser
- TLR:
- Toll-like receptor
Practice Gap
Acne vulgaris is a common disease seen in pediatric practices, and pediatricians should be able to develop management strategies using standard therapies, including retinoids.
Objectives
After completing this article, readers should be able to:
Describe the pathophysiology of acne.
Outline treatment options based on a patient’s clinical presentation.
Discuss mechanisms of action and adverse effects of common acne medications.
Explain treatment options for postacne sequelae.
Introduction
Acne vulgaris is a ubiquitous disease of the pilosebaceous unit, characterized by a long-term course with recurrences and relapses. It affects approximately 85% of adolescents and may persist until well into a patient’s 20s and 30s. (1)(2)(3) Psychological sequelae can be substantial and should not be underestimated. This common, very visible skin condition presents at a time when appearance is acutely important and noticeable disease marring that appearance is distressing. Embarrassment contributes to lower self-esteem and feelings of unattractiveness and worthlessness, which may be present not only during active flare-ups but also with long-lasting postinflammatory hyperpigmentation and permanent scarring. (4)
The aim of this review is to offer up-to-date information on pathophysiology, evaluation, and management strategies for this common disease.
The treatment of acne conglobata, acne fulminans, cloracne, drug-induced acne, hidradenitis …
Log in using your username and password
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.